3D culture model for Non-Alcoholic SteatoHepatitis (NASH) drug discovery
Lead Participant:
CN BIO INNOVATIONS LIMITED
Abstract
NASH presents a significant unmet medical need in more economically developed nations, affecting up to 5% of
the US population alone. There is currently no medical treatment for NASH, where the condition is a precursor
to cirrhosis and hepatocellular carcinoma, conditions with very poor prognoses. One key limiting factor in the
development of a treatment for NASH is a lack of suitable in vitro models. The project will produce a highly
representative, medium throughput, 3D perfused model of NASH using both primary human and induced
pluripotent stem cell derived hepatocytes, kupffer and stellate co-cultures. These models can be used in
collaboration with industry to enable highly effective drug discovery studies and macrosteatotically relevant
ADME/Toxicology studies.
the US population alone. There is currently no medical treatment for NASH, where the condition is a precursor
to cirrhosis and hepatocellular carcinoma, conditions with very poor prognoses. One key limiting factor in the
development of a treatment for NASH is a lack of suitable in vitro models. The project will produce a highly
representative, medium throughput, 3D perfused model of NASH using both primary human and induced
pluripotent stem cell derived hepatocytes, kupffer and stellate co-cultures. These models can be used in
collaboration with industry to enable highly effective drug discovery studies and macrosteatotically relevant
ADME/Toxicology studies.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| CN BIO INNOVATIONS LIMITED | £299,424 | £ 149,712 |
Participant |
||
| PIXL BIO LTD | £116,701 | £ 70,021 |
| UNIVERSITY COLLEGE LONDON | £137,880 | £ 137,880 |
People |
ORCID iD |